NCT02895750

Efficacity and Safety of Metformin XR in CKD Stage 1 to 3

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Centre Hospitalier Universitaire, Amiens · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

There is limited data availability on effect of Metformin XR on 24-h plasma glucose, and there is no available data in chronic kidney disease (CKD). The planned study aims to provide data on glucose plasma level in relation to metformin plasma level in Diabetes Type II patients.

Conditions

• Renal Insufficiency, Chronic

Interventions

Type	Name	Description
DRUG	Metformin	Metformin extended release tablets (Glucophage 500 mg; 750 mg; 1,000 mg) administrated during 6 to 12 weeks (CKD1 and 3B, respectively)

Timeline

• Start date: 2017-08-30
• Primary completion: 2022-01-08
• Completion: 2022-10-10
• First posted: 2016-09-12
• Last updated: 2025-09-19

Locations

1 site across 1 country: France